| Theme | Prognosis of Liver Diseases | |
|---|---|---|
| Title | Prognosis of Hepatocellular Carcinoma : Treatment with Selective Transcatheter Arterial Embolization | |
| Publish Date | 1997/10 | |
| Author | Yukihiro Shirota | First Department of Internal Medicine, School of Medicine, Kanazawa University |
| Author | Kenichi Kobayashi | First Department of Internal Medicine, School of Medicine, Kanazawa University |
| [ Summary ] | The prognosis of hepatocellular carcinoma (HCC) patients treated with selective transcatheter embolization (sTAE) in our institute is reviewed herein. The local recurrence rates of HCC after sTAE treatment were relatively lower than those after conventional TAE. The local recurrence rates 1 and 3 years after treatments amounted to 30.8% and 47.8%, respectively. However, 3 years after the treatments, the number of local recurrences reached a plateau, indicating that the treatments for local recurrence were sufficiently effective to inhibit recurrence and thereby contributed to good survival rates : survival rates 3 and 5 years after treatments were 70.9% and 48.5%, respectively. On the other hand, the 1- and 3-year rates of distant recurrences were 37.5 % and 67.7%, respectively, higher than those of local recurrences. Furthermore, most of the distant recurrences occurred in a multicentric pattern. In addition, sTAE could be performed repetitively. It is concluded that sTAE may be a useful anti-tumor treatment for local recurrences of HCC, contributing to better survival of patients. In conclusion, sTAE may be a useful anti-tumor treatment for local recurrence of HCC. |
|